What Vulketan Treats: Main Uses and Benefits

The therapeutic application of Vulketan (Ketanserin gel) is focused on providing localized support for tissue repair in challenging clinical contexts, addressing symptoms that lead to persistent skin defects. The medication is commonly used to support healing in chronic ulcer conditions.

Enhanced Healing for Chronic Ulcers

This medication is generally used as an adjunctive treatment for chronic skin ulcers that are refractory to standard care. This includes diabetic foot ulcers, venous stasis ulcers, and decubitus (pressure) ulcers, which are conditions marked by symptoms linked to organ-specific functional stress. The benefit provided to the patient is that it contributes to easing discomfort by supporting the process of wound closure of these long-standing, open wounds and reducing the overall symptom burden.

“The use is relevant in therapeutic contexts where the body's natural tissue formation has stalled.”

Support for Tissue Vitality and Growth

Vulketan is considered relevant in situations where the wound exhibits symptoms of impaired tissue healing and poor local vitality. It assists in promoting the formation of healthy, robust granulation tissue—the necessary base for new skin—and supports the process of epithelialization (new skin growth) over the defect. A specific therapeutic application is commonly used to help with the management of exuberant granulation tissue, a complication where excessive tissue growth impedes final wound closure.

Quick Fact: Support for Impaired Tissue Healing The medication may assist with the healing process by addressing the symptoms of compromised tissue vitality often seen in chronic wounds.

The official regulatory profile for Vulketan (Ketanserin Gel) defines eligibility based on its designation as a Veterinary Medicinal Product with the target species being Horses. The use of this specific labeled product is not established or approved for human populations.

Populations for whom use is Contraindicated

The medicine is formally contraindicated and must not be used in any individual with a known hypersensitivity to the active substance, Ketanserin, or any of its excipients. Official labeling also prohibits use on specific wound conditions:

• Deep or infected wounds.
• Wounds immediately following surgical procedures.

Restricted and Conditional Eligibility

Application is strictly conditional upon the wound status. If a fresh wound is bleeding, use is restricted until bleeding has ceased. Furthermore, the regulatory documents specify that if hyper-granulation tissue has developed, it must be surgically removed before treatment can begin.

Age and Physiological Status

Human-specific eligibility rules concerning age, renal, or hepatic impairment are not applicable to this product’s official prescribing information. For the designated target species, the product is officially permitted for topical use during both pregnancy and lactation.

The official regulatory profile for Vulketan (Ketanserin gel) establishes that for this specific topical formulation, there are no known systemic interactions with other medicinal products. This classification is consistent with the pharmacokinetic data showing only a negligible quantity of the active substance is absorbed after cutaneous application. Therefore, the label does not document any warnings regarding altered drug exposure or concentration when co-administered with other systemic medicines.

---

Official Status of Systemic Interactions

Interaction Type	Regulatory Status (Official Label)
Pharmacokinetic (e.g., CYP-mediated)	None known
Pharmacodynamic (Additive effects)	None known
Contraindicated Combinations	None listed
Food, Alcohol, or Herbal Products	Not documented

---

Administration Restriction

The primary constraint documented in the official prescribing information relates to a procedural incompatibility. In the absence of documented compatibility studies, the product is restricted and must not be mixed with any other medicinal product. This restriction is intended to preserve the physical and chemical integrity of the gel formulation and ensure its proper function upon application, confirming that this physical restriction is the sole mandatory interaction constraint defined in the regulatory context.

How Vulketan Works

Vulketan is a small molecule inhibitor that exhibits high-affinity, selective binding to the osteoclast-specific lysosomal cysteine protease, Cathepsin K (CTSK). CTSK is the principal enzyme responsible for the degradation of Type I collagen and other structural proteins that constitute the organic bone matrix during the process of bone resorption. The binding of Vulketan induces a non-competitive allosteric inhibition of CTSK's proteolytic activity.

By specifically modulating this enzymatic function, Vulketan slows the osteoclast's intrinsic ability to digest the demineralized bone surface. This reduction in Cathepsin K-mediated bone resorption shifts the dynamic physiological balance in bone remodeling, resulting in a relative decrease in bone matrix loss. The mechanism limits the structural changes associated with excessive osteoclast activity. The pharmacokinetic profile of Vulketan ensures sustained inhibition of the target enzyme, maintaining its selective effect on the bone remodeling unit.

The use of Vulketan (ketanserin 2.5 mg/g gel) is defined for external, topical administration (cutaneous use). The product is designated for use in horses, and its application protocol follows established product characteristics.

Administration and Dosing

The standard protocol dictates application twice daily (BID). The dosing principle requires the gel to completely cover the entire surface of the affected area and its edges; no specific volumetric dose is prescribed. The duration of use is not fixed but is defined by the need to continue application until the wound has fully healed.

Procedural Constraints

The instructions mandate specific steps before application. The affected area must be thoroughly cleaned with water before starting treatment, and must be washed with warm water prior to every subsequent application to remove the residual film of gel. Furthermore, treatment can only begin after local bleeding has ceased, and any hypergranulation tissue must be surgically excised prior to initiation. This procedural structure ensures that application conditions adhere to the product label.

Research evidence / Overview of studies for Vulketan

Evidence for Chronic Skin Ulcers (Venous, Decubitus, and Ischemic Types)

Research into Ketanserin gel for chronic skin ulcers has involved controlled clinical trials, including randomized double-blind studies, in which the treatment was studied in adult populations. These studies often focused on ulcers that have been slow to heal, such as those related to pressure, venous insufficiency, or restricted blood flow (ischemic ulcers). Researchers monitored key outcomes related to physical discomfort, including the formation of granulation tissue—the base required for new skin—and the extent of epithelialization.

Studies exploring this context reported measurements related to the initial velocity of wound closure and total reduction in ulcer area in comparison groups, such as a non-medicated control or placebo. Findings describe patterns observed in the studies and research highlights changes measured during the short-term defined time intervals, typically ranging from 8 to 12 weeks.

Evidence for Chronic Ulcers in Diabetic Patients

A specific body of research was evaluated for chronic ulcers in patients with diabetes, particularly diabetic foot ulcers. These studies included randomized controlled trials and comparative single-blind trials. The populations studied consisted of diabetic patients with foot ulcers, including specific cohorts presenting with underlying conditions like severe peripheral vascular compromise.

Research in this area examined outcomes related to physical discomfort by monitoring changes in ulcer size, the measured wound healing rate, and the occurrence of complications. Studies report how symptoms evolved in the observed populations, and data show patterns related to changes in the measured healing rate. However, the certainty remains low regarding the generalizability of these findings, as data for certain groups remain insufficient.

Long-Term Follow-up and Durability of Response

Clinical trials for topical Ketanserin have primarily focused on short-term to intermediate-term endpoints, typically evaluating outcomes over periods ranging from a few weeks up to six months. The evidence provides insight into short-term changes and symptom patterns, but limited information is available for long-term outcomes, such as recurrence rates of chronic ulcers or the stability of the repaired tissue over time.

Research Gaps and Remaining Uncertainty

The overall evidence landscape for Ketanserin gel is limited by several factors. Many of the studies conducted were characterized by sample sizes that were modest, meaning the research provides context about group patterns but not certainty about individual predictions. Evidence quality varies across studies, and systematic reviews have highlighted methodological differences, meaning comparative evidence is lacking or uncertain. As a result, certainty remains low regarding the full range of outcomes, and data are still emerging in several areas, highlighting the need for further, large-scale clinical investigation.

Key Studies & References Systematic reviews of wound care management: (2) dressings and topical agents used in the healing of chronic wounds

Common questions about Vulketan (FAQ)

Q: What is the full name of the active ingredient in Vulketan gel?

A: According to the official product information, the active substance is Ketanserin. It is incorporated into the gel formulation as Ketanserin tartrate.

Q: What specific type of ingredient makes up the base of the gel?

A: The gel utilizes an aqueous polymer base. Official documentation lists the excipients, which include Hypromellose, along with water, propylene glycol, and specific preservatives (methyl parahydroxybenzoate and propyl parahydroxybenzoate). Hypromellose is a type of polymer used to create the gel consistency.

Q: Does Vulketan have any officially documented side effects?

A: The official regulatory documentation for this topical product does not list any adverse reactions or side effects. The safety profile focuses instead on specific contraindications, such as a known hypersensitivity to the active substance, and required application precautions.

Q: What is the primary mechanism by which Ketanserin supports wound healing?

A: Studies and official information indicate that Ketanserin works primarily as a selective 5-HT₂ receptor antagonist. This mechanism is clinically recognized to support enhanced microcirculation (blood flow) in the damaged tissue, which in turn facilitates the process of epithelialization (new skin growth).

Q: What happens to the product after it has been opened for 28 days?

A: The stability of the gel is limited once the tube is first opened. The official product information states that the post-opening shelf life is 28 days, after which any remaining product must be discarded.

Q: What is the typical shelf life of Vulketan gel before the tube is opened?

A: The shelf-life of the veterinary medicinal product as packaged for sale (unopened) is three years, as stated in the official product information.

Q: What is the official withdrawal period for Vulketan in horses intended for food consumption?

A: The official regulatory documentation establishes the withdrawal period for this product. This means the official withdrawal period is zero days for meat/offal and zero hours for milk.

Q: Can Vulketan gel be applied by hand, or is an applicator tool required?

A: Official instructions recommend the use of disposable gloves when handling the product, which is consistent with application by hand or gloved hand. No specific applicator tool is mandated in the official prescribing information.

Q: Can the gel be used safely in pregnant or lactating animals?

A: The official prescribing information for this veterinary product states that it is indicated for topical use during both pregnancy and lactation in the target species.

The official regulatory instructions for Vulketan (Ketanserin gel) define specific conditions for storage and mandatory procedures for disposal.

Storage Requirements

The product must be kept out of the sight and reach of children and stored in its original container at a temperature not exceeding 30°C. The stability of the gel is strictly limited once the tube is first opened. The post-opening shelf life is only 28 days, after which any remaining product must be discarded.

Disposal Instructions

Disposal of unused or expired Vulketan must adhere to environmental protection standards. The medicine must not be disposed of via wastewater or household waste. All disposal must be carried out in accordance with national pharmaceutical waste requirements.